| Literature DB >> 36221377 |
Abstract
Serum anti-Müllerian hormone (sAMH) is a useful marker of ovarian reserve. In many patients, the sAMH levels gradually recover after falling to the lowest level after surgery (nadir phenomenon). This study aimed to analyze the factors related to sAMH recovery from the nadir after an ovarian cystectomy for endometriosis among Korean women. A total of 159 patients with ovarian endometriosis were included in the study. The sAMH levels were measured before surgery and at least twice within 12 months after the surgery. The patients were divided into two groups: those with recovery (nadir group) and those without recovery (reduction group). Postoperative recovery of the sAMH levels from the nadir was not related to the stage and bilaterality of the lesion, surgical methods, such as robot-assisted or laparoscopic surgery, or surgical time. In the nadir group, the level of preoperative cancer antigen 125 was significantly higher, and it decreased significantly after the surgery than in the reduction group (P = .02 and P = .02). Additionally, the postoperative C-reactive protein (CRP) level was significantly higher in the nadir group, and it increased significantly after the surgery than in the reduction group (P = .03 and P = .04). The increasing degree of perioperative CRP level showed a cutoff value on the receiver operating characteristic curve (0.735 mg/dL, area under curve = 0.604; P = .04). Increased serum CRP levels after surgery are significantly related to the recovery of sAMH levels from the nadir. Therefore, postoperative serum CRP level could be used as a marker to predict the sAMH nadir after surgery.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36221377 PMCID: PMC9542760 DOI: 10.1097/MD.0000000000030977
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1.Flow diagram for patient selection (*Dienogest or ethinyl estradiol). sAMH = Serum anti-Müllerian hormone.
Patient characteristics and clinical factors between the serum anti-Müllerian hormone nadir and reduction groups.
| Nadir group | Reduction group | ||
|---|---|---|---|
| Total patients (n) | 106 | 53 | |
| Age (yr) | 29.86 ± 6.20 | 29.57 ± 6.82 | .79 |
| Obstetric history | |||
| Gravida (n) | 0.41 ± 0.95 | 0.43 ± 1.01 | .62 |
| Parity (n) | 0.26 ± 0.68 | 0.25 ± 0.59 | .86 |
| Abortion (n) | 0.14 ± 0.45 | 0.25 ± 0.83 | .40 |
| Menarche (yr) | 13.23 ± 1.31 | 13.38 ± 1.43 | .51 |
| Dysmenorrhoea | 4.92 ± 2.66 | 5.19 ± 2.68 | .55 |
| rASRM stage (n) | |||
| I | 4 (3.8%) | 3 (5.7%) | .23 |
| II | 6 (5.7%) | 7 (13.2%) | |
| III | 13 (12.3%) | 9 (17.0%) | |
| IV | 83 (78.3%) | 34 (64.2%) | |
| Bilaterality of lesion (n) | |||
| Unilateral endometrioma | 56 (52.8%) | 29 (54.7%) | .87 |
| Bilateral endometrioma | 50 (47.2%) | 24 (45.3%) | |
| Total size of lesion (cm) | 7.12 ± 3.50 | 7.07 ± 3.17 | .95 |
| Method of surgery (n) | |||
| Robot-assisted cystectomy | 63 (59.4%) | 28 (52.8%) | .50 |
| Laparoscopy-assisted cystectomy | 43 (40.6%) | 25 (47.2%) | |
| Time of surgery (min) | 114.52 ± 48.37 | 122.49 ± 64.65 | .31 |
| Method of bleeding control (n) | |||
| Suture and hemostatic agent | 100 (94.3%) | 49 (92.5%) | .73 |
| Hemostatic agent alone | 6 (5.7%) | 4 (7.5%) | |
| Administration of GnRHa after surgery (n) | 75 (70.8%) | 36 (67.9%) | .86 |
| Medication after surgery | |||
| Dienogest (n) | 96 (90.6%) | 45 (84.9%) | .43 |
| Medication period (m) | 19.18 ± 11.30 | 21.04 ± 11.35 | .36 |
| Drospireonone/ethinyl estradiol (n) | 10 (9.4%) | 8 (15.1%) | .43 |
| Period of medication (m) | 26.60 ± 26.14 | 28.63 ± 24.39 | .87 |
Data are presented as means ± SDs or numbers.
rASRM = revised American Society for Reproductive Medicine, GnRHa = Gonadotropin-releasing hormone agonist.
Evaluated with Student t test or Mann–Whitney U test.
Evaluated with chi-square test or Fisher’s exact test.
Evaluated with visual analogue scale (VAS) score.
Comparison of inflammatory factors before and after the surgery, and the difference between the serum anti-Müllerian hormone nadir and reduction groups.
| Nadir group | Reduction group | ||
|---|---|---|---|
| WBC count (n) | |||
| Preoperative | 6233.21 ± 1625.26 | 6565.28 ± 1674.57 | .237 |
| Postoperative | 9250.38 ± 2690.38 | 8961.89 ± 2644.84 | .521 |
| Difference | 3017.17 ± 2495.01 | 2396.60 ± 2481.45 | .141 |
| ANC (n) | |||
| Preoperative | 3978.32 ± 1474.48 | 3994.90 ± 1403.89 | .946 |
| Postoperative | 7268.09 ± 2707.97 | 6879.39 ± 2553.16 | .404 |
| Difference | 3372.64 ± 2585.94 | 3067.02 ± 2368.79 | .492 |
| ESR (mm/h) | |||
| Preoperative | 17.05 ± 15.23 | 19.37 ± 15.83 | .386 |
| Postoperative | 3.48 ± 4.66 | 2.29 ± 0.83 | .776 |
| Difference | −9.74 ± 9.73 | −8.07 ± 9.49 | .454 |
| CRP (mg/dL) | |||
| Preoperative | 0.15 ± 0.30 | 0.24 ± 0.96 | .378 |
| Postoperative | 3.22 ± 3.21 | 2.32 ± 2.05 | .033 |
| Difference | 3.07 ± 3.20 | 2.05 ± 2.18 | .040 |
| CA-125 (U/dL) | |||
| Preoperative | 78.86 ± 99.78 | 52.93 ± 36.80 | .022 |
| Postoperative | 16.78 ± 13.67 | 23.88 ± 37.52 | .300 |
| Difference | −61.33 ± 109.03 | −25.77 ± 40.91 | .024 |
Data are presented as means ± SDs or numbers.
ANC = absolute neutrophil count, CA-125= cancer antigen 125, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, WBC = white blood cell.
Evaluated with Student t test.
Evaluated with Mann–Whitney U test.
Figure 2.Receiver operating characteristic curve for increased serum CRP and its cutoff value, which showed the nadir of serum AMH after ovarian cystectomy due to ovarian endometriosis (*Determined by the Youden’s index). AMH = anti-Müllerian hormone, CRP = C-reactive protein.